P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO. 2017; 1(1): 38-40 | DOI: 10.14744/ejmo.2017.43153

Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report

Hilmi Kodaz1, Muhammet Bekir Hacioglu2, Osman Kostek2, Bulent Erdogan2, Ebru Tastekin3, Cagnur Elpen Kodaz4, Irfan Cicin2
1Department of Medical Oncology, Acibadem Eskisehir Hospital, Eskisehir, Turkey, 2Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey, 3Department of Pathology, Trakya University Faculty of Medicine, Edirne, Turkey, 4Department of Health, Acibadem Eskisehir Hospital, Eskisehir, Turkey

Malignant eccrine porocarcinoma is a very rare tumor and the etiology is not known. Treatment is surgical removal of the tumor. The benefit of chemotherapy and radiotherapy is unclear. A 49-year-old male patient presented with the complaint of left inguinal swelling. Ultrasonography examination revealed 5x4 cm inguinal lymphadenopathy. The inguinal lymph nodes were excised. Pathology report indicated eccrine porocarcinoma. The patient was treated with cisplatin 40 mg/m2 week as well as concurrent radiotherapy for 5 weeks. After 6 weeks of dual therapy, liver metastases were detected. KRAS, NRAS, and BRAF tests were negative. Gemcitabine was administered at a dose of 1000 mg/m2 on days 1 and 8 every 21 days, and docetaxel was administered at a dose of 75 mg/m2 on day 8, every 21 days. There was progression after 2 cycles of chemotherapy. The patient lived 7 months. In this case, use of synchronous cisplatin and radiotherapy as adjuvant treatment could not prevent tumor metastasis. The combination chemotherapy of docetaxel and gemcitabine applied after metastatic disease development was ineffective.


Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report. EJMO. 2017; 1(1): 38-40

Corresponding Author: Hilmi Kodaz

Full Text PDF